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i.org/1presence of prediabetes mellitus (PreDM) combined with either an elevated triglyceride
(TG >1.7 mmol/l) or body mass index (BMI ‡27.0 kg/m2), to identify increased risk of
statin-associated type 2 diabetes mellitus (T2DM). Consequently, a retrospective analysis of
data from subjects without diabetes in the Treating to New Targets and the Stroke Pre-
vention by Aggressive Reduction in Cholesterol Levels randomized controlled trials was
performed, subdividing participants into 4 experimental groups: (1) normal fasting glucose
(NFG) and TG £1.7 mmol/l (42%); (2) NFG and TG >1.7 mmol/l (22%); (3) PreDM and TG
£1.7 mmol/l (20%); and (4) PreDM and TG >1.7 mmol/l (15%). Comparable groupings were
created substituting BMI values (kg/m2 <27.0 and ‡27.0) for TG concentrations. Patients
received atorvastatin or placebo for a median duration of 4.9 years. Incident T2DM, deﬁned
by developing at least 2 fasting plasma glucose (FPG) concentrations ‡126 mg/dl, an in-
crease in FPG ‡37 mg/dl, or a clinical diagnosis of T2DM, was observed in 8.2% of the total
population. T2DM event rates (statin or placebo) varied from a low of 2.8%/3.2% (NFG and
TG £1.7 mmol/l) to a high of 22.8%/7.6% (PreDM and TG >1.7 mmol/l) with intermediate
values for only an elevated TG >1.7 mmol/l (5.2%/4.3%) or only PreDM (12.8%/7.6%).
Comparable differences were observed when BMI values were substituted for TG con-
centrations. In conclusion, these data suggest that (1) the diabetogenic impact of statin
treatment is relatively modest in general; (2) the diabetogenic impact is accentuated rela-
tively dramatically as FPG and TG concentrations and BMI increase; and (3) PreDM, TG
concentrations, and BMI identify people at highest risk of statin-associated T2DM. 
2016 Elsevier Inc. All rights reserved. (Am J Cardiol 2016;118:1275e1281)Given widespread use of statin therapy and recent con-
cerns as to statin-associated type 2 diabetes (T2DM),1e5
identifying people at the greatest risk of developing
T2DM while on statins would provide useful clinical
information. Risk of incident T2DM in association with
statin therapy is increased in patients with higher blood
pressures and fasting plasma glucose (FPG) and triglyceride
(TG) concentrations,3 a constellation of abnormalities
closely associated with insulin resistance.6 Because insulin
resistance is an independent predictor of T2DM,7 having a
simple way of identifying an insulin-resistant subpopulation
before statin treatment should be clinically useful. Hyper-
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0.1016/j.amjcard.2016.07.054with direct measurements of insulin resistance,8e10 but the
absence of a standardized insulin assay limits its clinical
utility.11 Prevalence of insulin resistance is increased in
patients with prediabetes mellitus (PreDM),12,13 and a
diagnosis of PreDM, deﬁned by an FPG concentration
5.6 mmol/l (100 mg/dl) and <7.0 mmol/L (126 mg/dl),
predicts statin-associated T2DM.14 Although this FPG cut
point provides a useful ﬁrst step in efforts to identify
enhanced risk of statin-associated T2DM, PreDM is a het-
erogeneous entity, and not all subjects with this diagnosis
are insulin resistant.12,13 Consequently, we hypothesized
that combining a diagnosis of PreDM with an additional
index of insulin resistance would more effectively identify a
subset of patients with PreDM who were further enriched
with insulin resistance and at even greater greatest risk of
statin-associated T2DM. For this purpose, we evaluated the
impact of combining a diagnosis of PreDM with a mea-
surement of either fasting TG concentration >1.7 mmol/l
(>150 mg/dl) or a body mass index (BMI) 27.0 kg/m2,
either one of which is associated with insulin resistance.15,16
The goal of this analysis was to extend our earlier ﬁndings14
by determining the degree to which combining PreDM with
either fasting plasma TG concentration >1.7 mmol/l or a
BMI 27.0 kg/m2 improved identiﬁcation of subjects most
likely to develop statin-associated T2DM.www.ajconline.org
Table 1
Baseline characteristics of the combined TNT and SPARCL population by glycemic status and TG concentration
Fasting glucose (mmol/L) <5.6 <5.6 5.6 - <7.0 5.6 - <7.0
Triglycerides (mmol/L) 1.7 >1.7 1.7 >1.7
Total (n¼11354) (N¼4782) (N ¼ 2303) (N ¼ 2544) (N ¼ 1725)
Male 8495 (74.8%) 3521 (73.6%) 1632 (70.9%) 2039 (80.2%) 1303 (75.5%)
White 10778 (94.9%) 4489 (94.0%) 2219 (96.4%) 2431 (95.6%) 1639 (95.0%)
Age (years) 61.2  9.9 61.5  10.2 59.2  10.0 62.8  9.3 60.8  9.5
BMI (kg/m2) 27.8  4.3 26.7  4.0 28.3  4.2 28.1  4.2 29.6  4.6
Fasting glucose
(mmol/L)
(mg/dl)
5.38  0.59
96.8  10.6
5.01  0.38
90.18  6.84
5.03  0.37
90.54  6.66
5.95  0.34
107.10  6.12
6.01  0.37
108.18  6.66
Systolic BP (mmHg) 132  18 131  18 131.4  17 134  19 133.9  17
Diastolic BP (mmHg) 79  10 79  10 79.6  10 79.3 10 80.3  10
Smoker
Never 3252 (28.6%) 1554 (32.5%) 631 (27.4%) 691 (27.2%) 376 (21.8%)
Ex 6345 (55.9%) 2517 (52.6%) 1223 (53.1%) 1536 (60.4%) 1069 (62.0%)
Current 1757 (15.5%) 711 (14.9%) 449 (19.5%) 317 (12.5%) 280 (16.2%)
Hypertension 6033 (53.1%) 2329 (48.7%) 1256 (54.5%) 1426 (56.1%) 1022 (59.3%)
Total Cholesterol
(mmol/L)
(mg/dl)
4.84  0.80
187.16  30.94
4.74  0.80
183.29  30.93
5.12  0.81
197.99  31.32
4.66  0.80
180.20  30.94
5.08  0.75
196.44  29.00
LDL-C
(mmol/L)
(mg/dl)
2.85  0.67
110.21  25.91
2.85  0.67
110.20  25.91
2.87  0.70
110.98  27.07
2.80  0.67
108.27  25.91
2.85  0.65
110.21  25.14
HDL-C
(mmol/L)
(mg/dl)
1.27  0.31
49.11  11.99
1.35  0.34
52.20  131.5
1.17  0.28
45.24  10.83
1.32  0.31
51.04  11.99
1.14  0.26
44.08  10.05
TG
(mmol/L)
(mg/dl)
1.64  0.82
145.26  72.63
1.19  0.30
105.40  26.57
2.42  0.99
214.35  87.69
1.22  0.29
108.10  25.69
2.44  0.71
216.12  62.89
All values depicted as mean  SD, unless otherwise speciﬁed.
BMI ¼ body mass index; BP ¼ blood pressure; HDL-C ¼ high density lipoprotein-cholesterol; LDL-C ¼ low-density lipoprotein-cholesterol;
TG ¼ triglycerides.
1276 The American Journal of Cardiology (www.ajconline.org)Methods
The study population consisted of patients without dia-
betes mellitus (DM) pooled from the Treating to New Tar-
gets (TNT) and the Stroke Prevention by Aggressive
Reduction in Cholesterol Levels (SPARCL) trials, the
design and ﬁndings of which have been published.17,18 The
TNT study17 randomized 10,001 patients with coronary
disease to atorvastatin 10 or 80 mg/day, whereas the
SPARCL study randomized 4,731 patients with stroke or
transient ischemic attack to atorvastatin 80 mg or placebo.18
Both studies had a median follow-up of 4.9 years. Patients
with DM (n ¼ 2,843) at baseline were excluded from the
combined cohort, and 489 were excluded because fewer
than 2 postbaseline FPG measurements were available or
because baseline TG (n ¼ 4) or FPG measurements were
missing (n ¼ 42).
Subjects were classiﬁed as having normal fasting
glucose (NFG; FPG <5.6 mmol/l: n ¼ 7,085) or PreDM
(n ¼ 4,269) on the basis of their FPG as deﬁned by
American Diabetes Association criteria.19 Follow-up visits
occurred at week 12 and at months 6 and 9 (in TNT), and at
week 12 in the ﬁrst year and every 6 months thereafter.
FPG was measured before statin treatment, annually, and at
the end of the studies. Incident T2DM was deﬁned pro-
spectively as 2 postbaseline FPG measurements
7.0 mmol/l or at least 1 postbaseline FPG 2.0 mmol/l
above baseline.20 Subjects were also considered to havedeveloped T2DM on the basis of adverse event reporting or
new medication for diabetes.
The analysis involved comparison of incident T2DM on
the basis of baseline FPG plus either TG concentration or
BMI value. Thus, comparisons were between patients sub-
divided into 4 subgroups on the basis of their FPG and TG
concentration: NFG and TG 1.7 mmol/l; NFG and TG
>1.7 mmol/l; PreDM and TG 1.7 mmol/l; and PreDM and
TG >1.7 mmol/l. In addition, comparisons were made
between patients subdivided into 4 subgroups on the basis of
their baseline FPG and BMI values (NFG and BMI
<27.0 kg/m2; NFG and BMI  27.0 kg/m2; PreDM BMI <
27.0 kg/m2, and PreDM and BMI  27.0 kg/m2). Com-
parisons were also made using these same groupings in
SPARCL to compare incident T2DM in statin-treated versus
placebo-treated subjects.
Univariate and multivariate adjusted Cox proportional
hazards models were used to calculate hazard ratios (HRs)
and 95% conﬁdence intervals (CIs) to compare incident
T2DM between the groups. Models were adjusted for fac-
tors that may have been independently associated with
development of T2DM including hypertension, high-density
lipoprotein cholesterol (HDL-C), and study.
Results
Baseline demographic and metabolic characteristics of
the 4 statin-treated groups, subdivided on the basis of
Table 2
Baseline characteristics of the combined TNT and SPARCL population by glycemic status and BMI
Fasting Glucose (mmol/L) <5.6 <5.6 5.6 - <7.0 5.6 - <7.0
BMI (kg/ m2) <27 27 <27 27
Total (n¼11281) (N¼3697) (N ¼ 3348) (N ¼ 1592) (N ¼ 2644)
Male 8450 (74.9%) 2691 (72.8%) 2439 (72.6%) 1251 (78.6%) 2069 (78.2%)
White 10709 (94.4%) 3522 (95.3%) 3150 (94.1%) 1530 (96.1%) 2507 (94.8%)
Age (years) 61.2  9.9 61.9  10.3 59.6  9.9 63.3  9.6 61.1  9.2
BMI (kg/m2) 27.8  4.3 24.3  2.0 30.4  3.5 24.7  1.7 31.1  3.7
Fasting glucose
(mmol/L)
(mg/dl)
5.38  0.59
96.84  10.62
5.0  0.38
90  6.84
5.03  0.37
90.54  6.66
5.94  0.33
106.90  5.93
6.01  0.33
108.10  6.0
Systolic BP (mmHg) 132.42  17.8 131  18.0 131.96  17.1 133.1  18.6 134.59  17.7
Diastolic BP (mmHg) 79.26  10.0 78.06  9.8 80.1  10.0 78.5  10.2 80.4  9.8
Smoker
Never 3225 (28.6%) 1174 (31.8%) 997 (29.8%) 428 (26.9%) 626 (23.7%)
Ex 6318 (56.0%) 1853 (50.1%) 1873 (55.9%) 903 (56.7%) 1689 (63.9%)
Current 1738 (15.4%) 670 (18.1%) 478 (14.3%) 261 (16.4%) 329 (12.4%)
HTN 5991 (53.1%) 1651 (44.7%) 1915 (57.2%) 786 (49.4%) 1639 (62.0%)
Total Cholesterol
(mmol/L)
(mg/dl)
4.84  0.81
187.16  31.32
5.28  0.14
204.18  5.41
4.82  0.80
186.39  30.94
4.87  0.83
188.32  32.10
4.79  0.76
185.23  29.39
LDL-C
(mmol/L)
(mg/dl)
2.83  0.67
109.43  25.91
2.87  0.70
110.98  27.07
2.82  0.66
109.05  25.52
2.87  0.70
110.98  27.07
2.78  0.63
107.50  24.36
HDL-C
(mmol/L)
(mg/dl)
1.27  0.32
49.11  12.37
1.34  0.35
51.82  13.53
1.24  0.30
47.95  11.60
1.30  0.31
50.27  11.99
1.20  0.27
46.40  10.44
TG
(mmol/L)
(mg/dl)
1.62  0.81
143.49  71.74
1.45  0.65
128.43  57.57
1.71  0.98
151.46  86.80
1.54  0.71
136.40  62.89
1.79  0.79
158.55  69.97
All values depicted as mean  SD, unless otherwise speciﬁed.
BMI ¼ body mass index; BP ¼ blood pressure; HDL-C ¼ high density lipoprotein-cholesterol; HTN ¼ hypertension; LDL-C ¼ low-density lipoprotein-
cholesterol; TG ¼ triglycerides.
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tration or BMI, are compared in Table 1 (TG concentration)
and Table 2 (BMI). In Table 1, the largest group comprised
people with NFG and TG 1.7 mmol/l (42%), with the
fewest subjects having PreDM and TG >1.7 mmol/l (15%).
The 4 groups were reasonably comparable in terms of age,
gender, and race. BMI was highest in those with PreDM and
TG >1.7 mmol/l and lowest in subjects with NFG and TG
1.7 mmol/l. By selection, FPG was highest in those with
PreDM, with higher TG concentrations in those selected for
that characteristic. Low-density lipoprotein cholesterol
(LDL-C) concentration was reasonably comparable across
the 4 groups, and HDL-C concentrations were lowest in the
2 groups with elevated TG concentrations.
Similar comparisons are provided in Table 2, evaluating
differences in the 4 statin-treated groups that varied in terms
of glucose tolerance status and BMI. In this instance, the
largest group consisted of people with NFG and a BMI
27 kg/m2 (33%), with the smallest group comprising those
with PreDM and a BMI 27.0 kg/m2 (14%). The 4 groups
were again comparable in terms of age, gender, and race.
People with NFG and BMI 27 kg/m2 and PreDM and BMI
27 kg/m2 had fairly comparable average BMI values.
Baseline total cholesterol and HDL-C levels were compa-
rable across the 4 groups. Baseline TG concentrations were
highest in the PreDM and BMI 27 kg/m2 group and lowest
in people with NFG and BMI <27 kg/m2.There were 939 incident cases (8.2%) of T2DM identi-
ﬁed during the median follow-up of 4.9 years. Results in
Figure 1 indicate that the incidence of T2DM was lowest in
statin-treated patients with NFG and TG 1.7 mmol/l
(2.8%), increasing progressively to 5.2%, 12.8%, and
22.8%, in those with only a TG concentration >1.7 mmol/l,
with only PreDM, and with combined PreDM and a TG
concentration >1.7 mmol/l, respectively.
There was little or no increased risk of statin treatment in
those with NFG compared to placebo. However, in those
with PreDM, there was a substantial increased baseline risk
for incident T2DM even with placebo treatment, for
example, incident T2DM occurred in 7.6% of placebo-
treated patients with PreDM and TG 1.7 mmol/l and
17.9% of placebo patients with PreDM and TG >1.7 mmol/
l. Statin treatment markedly accentuated this risk in those
with PreDM compared to placebo. For instance, 22.8% of
subjects with PreDM and TG >1.7 mmol/l developed
incident T2DM, a 27% increased risk versus those getting
placebo therapy.
HRs in statin-treated subjects were calculated to evaluate
the statistical signiﬁcance of the ﬁndings in Figure 1 and are
summarized in Figure 2. Statin treatment in patients with
either a TG concentration >1.7 mmol/L or PreDM or
PreDM and TG concentration >1.7 mmol/l was associated
with a signiﬁcantly (p <0.001) greater HR for developing
T2DM compared to those with NFG and TG 1.7 mmol/l.
Figure 1. Incident T2DM according to baseline presence of PreDM and TG concentrations. Comparison of the rates of incident T2DM as a function of
glycemic status (NFG vs PreDM) and plasma TG concentration (1.7 vs >1.7 mmol/l) in the 4 experimental groups, with each group stratiﬁed by treatment,
placebo or atorvastatin.
Figure 2. Hazard for T2DM according to baseline presence of PreDM and
TG concentrations. Compared to reference (NFG, TG 1.7 mmol/l), all the
other groups are signiﬁcantly different (p <0.001). HRs (95% CIs) are 1.5
(1.2 to 2.0), 4.0 (3.3 to 4.9), and 6.7 (5.4 to 8.2), respectively. Models were
adjusted for the following characteristics: BMI, HDL-C concentration,
history of hypertension, and study.
1278 The American Journal of Cardiology (www.ajconline.org)Furthermore, the HRs increased progressively (p <0.001),
from those with only a high TG, to only PreDM, to the
highest HR when both PreDM and TG >1.7 mmol/l were
present at baseline (HRs [95% CIs] are 1.5 [1.2 to 2.0], 4.0
[3.3 to 4.9], and 6.7 [5.4 to 8.2], respectively).
Figure 3 depicts rates of incident T2DM according to
fasting glucose concentration and BMI, with results com-
parable to those seen in Figure 1. Incident T2DM also
increased in a parallel fashion in the same 4 experimental
groups treated with placebo, and these changes were
accentuated with statin therapy. In subjects with NFG, the
overall rate of incident T2DM was relatively low and fairly
consistent (ranging from 2.6% to 4.6%) whether patients
were treated with statins and/or BMI was 27 kg/m2. The
lowest rate of T2DM incidence in statin-treated patients was
seen in people with NFG and BMI <27 kg/m2, was higher
in those with NFG and BMI 27 kg/m2, and progressively
increased in the PreDM and BMI <27 kg/m2 and PreDM
and BMI  27 kg/m2 groups. The highest absoluteincidence of T2DM (20.5%) was seen in the subjects with
PreDM and BMI 27 kg/m2, which was 22% higher than
those in the same category treated with placebo.
Adjusted HRs of incident T2DM in the 4 groups of
patients in whom BMI values were combined with PreDM
are demonstrated in Figure 4, with an overall pattern mir-
roring the HR trend seen with TG levels in Figure 2. The
HR (95% CI) was lowest in people with NFG and BMI
<27 kg/m2, then progressively increased to 1.4 (1.1 to 1.9)
with NFG and BMI 27 kg/m2 and 3.5 (2.7 to 4.5) in those
with PreDM and BMI <27 kg/m2 (p <0.001). People with
both PreDM and BMI 27 kg/m had the highest HR of 7.0
(5.6 to 8.6).Discussion
These results provide new information of both concep-
tual and clinical relevance concerning the relation among
insulin resistance, statin treatment, and T2DM. At the con-
ceptual level, perhaps the most informative ﬁnding was the
comparison of incident T2DM in patients treated with pla-
cebo versus statin. Focusing on Figures 1 and 3, the event
rates of T2DM, when treated with either statin or placebo,
were low in subjects with NFG, who had a TG concentra-
tion 1.7 mmol/l or a BMI <27.0 kg/m2. T2DM event rates
were somewhat greater in subjects with NFG and either an
elevated TG concentration or BMI, even more so in those
with PreDM alone, and the differences between statin and
placebo accentuated in these groups. However, incident
T2DM was substantially higher in those with PreDM plus
either an elevated BMI or TG concentration, associated with
the greatest difference between statin and placebo treatment.
These data support the conclusion that the diabetogenic
impact of statin treatment is relatively modest in the most
general sense but is accentuated relatively dramatically as
plasma glucose, TG concentrations and BMI increase.
The results of this analysis also provide important clinical
information to guide efforts aimed at minimizing the adverse
effects of statin therapy. In essence, there appears to be 4
Figure 3. Incident T2DM according to baseline presence of PreDM and BMI. Comparison of the rates of incident T2DM as a function of glycemic status (NFG
vs PreDM) and BMI (<27 vs 27 kg/m2) in the 4 experimental groups, with each group stratiﬁed by treatment, placebo or atorvastatin.
Figure 4. Hazard for T2DM according to baseline presence of PreDM and
BMI. Compared to reference (NFG, BMI <27 kg/m2), all the other groups
are signiﬁcantly different (p <0.001). HRs (95% CIs) are 1.4 (1.1 to 1.9),
3.5 (2.7 to 4.5), and 7.0 (5.6 to 8.6), respectively. Models were adjusted for
the following characteristics: HDL-C concentration, history of hyperten-
sion, and study.
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T2DM. We have created a simple 4-tier category system
for classiﬁcation of risk, with category 1 being lowest risk
and category 4 being highest risk. Category 1 includes the
majority (w40%) of statin-treated subjects who had a
normal FPG, were not overweight or obese, and had a TG
concentration 1.7 mmol/l or BMI < 27 kg/m2. The dia-
betic event rate was low (w3%) in these patients (Figures 1
and 3) and essentially identical to the rates in placebo-
treated subjects. At the other extreme, category 4 consists
of statin-treated participants who had PreDM plus either an
elevated TG (w15%) concentration or excess adiposity
(w20%) The diabetic event rate was more than 5-fold
higher in these patients compared to the low-risk group,
category 1, and was accentuated in statin-treated patients.When presented alone, the other 3 indexes (PreDM, TG
>1.7 mmol/l, or BMI 27.0 kg/m2) identiﬁed patients
whose diabetic event rates were intermediate between the
high- and low-risk groups. However, because PreDM alone
seemed to be associated with a higher diabetic event rate
compared to increases in either BMI or TG concentration, it
seemed reasonable to assign it to category 3, with the other 2
isolated abnormalities making up category 2.
How best to use this information is at the discretion of the
individual health care provider. However, several general-
izations can be made. Obtaining these simple measurements
before initiating statin treatment provides considerable
insight as to degree of risk of incident T2DM in a given
patient. Once the risk category has been determined, it is
possible to tailor an appropriate clinical plan to follow pa-
tients in whom statin therapy has been initiated. Thus, it
would seem prudent to monitor glycemic status more
frequently in those at greatest risk of T2DM (category 4)
and to consider other pharmacological and non-
pharmacological interventions to reduce risk. For example,
aggressive effort to overcome excess adiposity and
encourage more physical activity was shown in the Diabetes
Prevention Program to delay or prevent incident T2DM in
high-risk groups.21 The importance of having the ability to
initiate interventions aimed at decreasing risk of T2DM in
statin-treated patients identiﬁed at enhanced risk is under-
lined by the ﬁnding that weight gain predicted incident
T2DM in the TNT study.22
Although the results of our analysis provide straight-
forward clinical information concerning the relative risk of
T2DM following initiation of statin treatment, their path-
ophysiological implications are less clear. T2DM occurs
when insulin-resistant subjects cannot maintain the degree
of hyperinsulinemia required to prevent decompensation of
1280 The American Journal of Cardiology (www.ajconline.org)glucose tolerance.8,9 Cederberg et al.,23 using surrogate
estimates, reported that both insulin sensitivity and insulin
secretion decreased in statin-treated patients. If we accept
the view that statins have an untoward effect on insulin
action and secretion, 2 recent reports provide an intriguing
mechanistic explanation. Swerdlow et al.,24 based on evi-
dence from genetic analysis and randomized trials,
concluded that the increased risk of T2DM noted with
statin usage is at least “partially explained by hydrox-
ymethylglutaryl coenzyme A reductase inhibition.” These
ﬁndings suggest that the adverse effects of statins on car-
bohydrate metabolism is somehow tied in to their mecha-
nism of action on LDL-C concentration, an observation
that complements the recent ﬁnding that the prevalence of
type 2 diabetes was reduced in subjects with familial hy-
percholesterolemia.25 In the latter study, it was suggested
that decreased LDL-receptoremediated transmembrane
transport in patients with familial hypercholesterolemia
decreases likelihood of the detrimental accumulation of
cholesterol in the pancreatic b-cell, thus maintaining in-
sulin secretory function. Conversely, increased trans-
membrane uptake of cholesterol associated with statin
treatment might play an important role in decreasing in-
sulin action and/or insulin secretory function. The possi-
bility that statin-associated T2DM is mechanistically
intrinsic to the therapeutic effect of statins on decreasing
plasma LDL-C is both intriguing and worthy of further
evaluation.
Niacin usage in the treatment of dyslipidemic patients
has also been associated with an increase in incident
T2DM.26 Furthermore, based on this work of Goldberg and
Jacobson, it appears that incident T2DM in niacin-treated
patients is also associated with a loss of insulin sensi-
tivity. Thus, measurement of FPG and TG concentrations
would also seem to be useful in identifying those patients at
the greatest risk of incident in T2DM when treated with
niacin.
Important questions concerning the relation between
statin usage and T2DM remain unanswered. For example,
do statins impair insulin action, secretion, or both? Is the
putative adverse effect of statins on insulin action or
secretion accentuated in subjects with PreDM compared to
those with NFG, or is the impact of statins the same, and
incident T2DM more likely to occur in those with PreDM
because of their inherent increased risk? Interesting as
these are, the untoward effects on glucose homeostasis
associated with statin use should not obscure the substan-
tial and unequivocal beneﬁts of statin treatment on
decreasing cardiovascular disease.3e5,14 Hopefully, the
availability of a simple means to identify people at high
risk to develop statin-associated T2DM will lead to tar-
geted interventions (such as intensive weight loss) to
decrease this risk.
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